agenus
initiates
rolling
bla
submission
balstilimab
recurrent
metastatic
cervical
cancer
lexington
globe
newswire
agenus
nasdaq
agen
company
extensive
pipeline
checkpoint
antibodies
cell
therapy
adjuvants
vaccines
designed
activate
immune
response
cancers
infections
announced
initiation
rolling
submission
biologics
license
application
bla
food
drug
administration
fda
balstilimab
alone
treatment
recurrent
metastatic
cervical
cancer
data
largest
phase
trial
patients
refractory
cervical
cancer
presented
today
european
society
medical
oncology
esmo
virtual
congress
https
data
patients
treated
balstilimab
monotherapy
achieved
response
rates
positive
patients
treated
patients
support
balstilimab
bla
filing
balstilimab
novel
human
monoclonal
antibody
demonstrated
promising
clinical
benefit
second
line
treatment
cervical
cancer
initiation
rolling
bla
exciting
step
forward
agenus
closer
making
therapies
commercially
available
patients
cervical
cancer
limited
treatment
options
available
said
jennifer
buell
president
coo
agenus
continue
collaborate
leading
kols
fda
efforts
make
treatments
available
rolling
submission
allows
agenus
submit
section
bla
completed
enables
fda
review
submitted
sections
parallel
agenus
completion
balance
bla
application
american
cancer
society
estimates
around
new
cases
invasive
cervical
cancer
diagnosed
year
nearly
cervical
cancer
deaths
population
needs
new
therapies
safely
provide
clinical
benefit
across
patients
agenus
agenus
company
focused
discovery
development
therapies
engage
body
immune
system
fight
cancer
company
vision
expand
patient
populations
benefiting
cancer
immunotherapy
pursuing
combination
approaches
leverage
broad
repertoire
antibody
therapeutics
adoptive
cell
therapies
agentus
therapeutics
subsidiary
proprietary
cancer
vaccine
platforms
company
equipped
suite
antibody
discovery
platforms
gmp
manufacturing
facility
capacity
support
clinical
programs
agenus
headquartered
lexington
information
please
visit
twitter
handle
information
may
important
investors
routinely
posted
website
twitter
statements
press
release
contains
statements
made
pursuant
safe
harbor
provisions
federal
securities
laws
including
statements
regarding
clinical
development
regulatory
plans
timelines
statements
subject
risks
uncertainties
could
cause
actual
results
differ
materially
risks
uncertainties
include
among
others
factors
described
risk
factors
section
recent
quarterly
report
form
annual
report
form
filed
securities
exchange
commission
agenus
cautions
investors
place
considerable
reliance
statements
contained
release
statements
speak
date
press
release
agenus
undertakes
obligation
update
revise
statements
extent
required
law
statements
expressly
qualified
entirety
cautionary
statement
contact
